HGH 191AA in the Peptides UK Market: Somatropin Science, Evidence and Regulation
HGH 191AA in the Peptides UK Market: Somatropin Science, Evidence and Regulation
“HGH 191AA” is a commercial and research-market description usually intended to refer to the 191-amino-acid form of human growth hormone. In regulated medicine, the corresponding active substance is generally called somatropin. Somatropin is an established prescription biological medicine for defined endocrine conditions, but a laboratory vial carrying the words HGH 191AA should not be assumed to match a licensed product in identity, folding, potency, purity or safety.
Direct Answer
HGH 191AA usually means the predominant 22-kilodalton form of human growth hormone, a single-chain protein containing 191 amino acids. Recombinant versions with the same amino-acid sequence are known pharmaceutically as somatropin.
Somatropin is an established biological medicine. In the UK, licensed products are used under specialist supervision for particular forms of childhood growth failure and for carefully diagnosed growth hormone deficiency in adults.
The term HGH 191AA is not itself a complete medicinal-product specification. It says nothing about whether the protein is correctly folded, whether its two disulphide bonds are present, whether aggregates or bacterial impurities remain, whether the stated quantity is accurate or whether the product has biological potency.
Evidence for prescribed somatropin in diagnosed endocrine conditions should not be used to validate unlicensed products marketed for bodybuilding, anti-ageing, fat loss, athletic performance or general wellbeing. Those are different uses with different evidence and risk considerations.
HGH 191AA Key Points
The central facts needed to distinguish somatropin science from research-market claims.
What Is HGH 191AA?
The term describes an amino-acid chain length rather than a complete product standard.
Human growth hormone is a protein produced naturally by somatotroph cells in the anterior pituitary gland. Its secretion is pulsatile, meaning that blood concentrations rise and fall rather than remaining constant throughout the day.
The predominant naturally circulating form has a molecular mass of approximately 22 kilodaltons and contains 191 amino-acid residues. This is the form usually intended when a laboratory catalogue or commercial page uses the expression “HGH 191AA”.
Recombinant human growth hormone with the same amino-acid sequence is called somatropin. Recombinant DNA technology uses a genetically engineered production organism, followed by protein recovery, purification, folding and quality testing.
“191AA” therefore describes only one aspect of the substance. It does not establish that the protein has the correct three-dimensional structure or the biological characteristics of licensed somatropin.
How HGH 191AA Appears in the Peptides UK Market
The research-market label may resemble medicine terminology without demonstrating medicine-level quality.
Within Peptides UK search results, HGH 191AA is often grouped with short research peptides such as BPC-157, CJC-1295 or growth hormone fragments. Scientifically, this grouping can be misleading because full-length human growth hormone is a substantially larger and more complex biological protein.
Research-market vials may be described using terms such as recombinant HGH, somatropin, 191 amino acids, high purity or laboratory grade. None of these phrases alone proves that the product is equivalent to a licensed medicine.
A licensed somatropin product must be supported by validated manufacturing, potency, purity, stability and clinical data. It is released through a regulated quality system and supplied with approved product information.
A research-market vial may provide only a generic high-performance liquid chromatography result or an unverified certificate. That may not evaluate protein folding, aggregates, host-cell proteins, bacterial DNA, biological potency or microbiological quality.
The name does not prove equivalence
A vial labelled HGH 191AA is not automatically biosimilar to an authorised somatropin medicine. Biosimilarity requires extensive analytical, functional and clinical comparison with an approved reference biological medicine.
Is HGH 191AA a Peptide or a Protein?
Growth hormone is technically a polypeptide, but it is more accurately described as a protein hormone.
Peptides and proteins are both chains of amino acids. The distinction is not defined by a universally fixed numerical boundary, but shorter chains are generally called peptides while longer, folded and functionally complex chains are described as proteins.
At 191 amino acids and approximately 22 kilodaltons, human growth hormone is normally classified as a protein. Its biological function depends on its three-dimensional conformation and internal disulphide bridges.
Calling HGH 191AA a “research peptide” may be commercially convenient, but it risks obscuring the additional analytical complexity associated with recombinant proteins.
Why protein complexity matters
A short synthetic peptide can often be assessed primarily through sequence, molecular mass and chemical purity. A recombinant protein also requires detailed evaluation of folding, higher-order structure, aggregates, biological activity and production-system contaminants.
History of Human Growth Hormone Research
The transition from pituitary-derived hormone to recombinant somatropin changed both supply and safety.
Pituitary-Derived Growth Hormone
Early treatment relied on growth hormone extracted from human pituitary glands collected after death. Supplies were limited and manufacturing depended on pooled biological tissue.
Recognition of Creutzfeldt–Jakob Disease Risk
In 1985, authorities stopped distribution of pituitary-derived human growth hormone after cases of Creutzfeldt–Jakob disease were associated with contaminated historical preparations.
Recombinant DNA Production
Recombinant production made it possible to manufacture human growth hormone without relying on pituitary tissue.
Early Methionyl Products
Some early recombinant forms contained an additional N-terminal methionine, producing a 192-residue molecule commonly associated with the name somatrem.
Development of Somatropin
Improved recombinant processes produced the 191-residue sequence matching the predominant pituitary human growth hormone.
Biosimilars and Long-Acting Products
Subsequent development has included biosimilar daily somatropin and longer-acting growth hormone products. These require product-specific regulatory evidence and should not be grouped together solely because they influence the growth hormone receptor.
Molecular and Scientific Profile
The mature 22 kDa hormone is a folded, non-glycosylated protein with two internal disulphide bridges.
Somatropin
Somatropin is recombinant human growth hormone whose amino-acid sequence corresponds to the predominant 22 kDa pituitary hormone.
Two Disulphide Bonds
Four cysteine residues form two intramolecular disulphide bridges. Regulatory assessments identify bonds between Cys53 and Cys165, and between Cys182 and Cys189.
Correct bond formation contributes to the hormone’s stable three-dimensional shape.
| Generic medicine name | Somatropin |
|---|---|
| Common research-market term | HGH 191AA |
| Protein length | 191 amino-acid residues |
| Approximate molecular weight | 22,125 daltons |
| Chain structure | Single-chain protein |
| Glycosylation | Non-glycosylated |
| Disulphide bridges | Cys53–Cys165 and Cys182–Cys189 |
| Primary biological target | Growth hormone receptor |
| Important downstream mediator | Insulin-like growth factor 1, commonly called IGF-1 |
Natural human growth hormone is not represented by only one circulating molecular form. A smaller 20 kDa isoform and other variants also occur naturally. “191AA” refers specifically to the predominant 22 kDa form.
HGH 191AA Compared With 192AA Growth Hormone
The one-residue difference reflects the history of recombinant manufacturing.
| Feature | 191AA Somatropin | 192AA Methionyl Growth Hormone |
|---|---|---|
| Residue count | 191 | 192 |
| N-terminal sequence | Matches the predominant mature human pituitary hormone | Contains an additional methionine |
| Common pharmaceutical term | Somatropin | Historically associated with somatrem or met-rhGH |
| Current relevance | Standard sequence for many licensed recombinant products | Primarily of historical and analytical interest |
| Can HPLC alone distinguish them? | Not reliably in every method; intact mass and peptide mapping provide stronger identity evidence | |
The phrase “191AA” is commonly used in marketing to suggest that a product matches natural growth hormone. Residue count is relevant, but it remains only one part of a complete protein-characterisation programme.
How Does Human Growth Hormone Signal?
Growth hormone has direct receptor effects and indirect effects mediated partly through IGF-1.
Growth Hormone Receptor Binding
Human growth hormone binds to the growth hormone receptor on responsive cells. Receptor engagement changes the arrangement of receptor components and activates intracellular signalling proteins.
Important pathways include Janus kinase 2, commonly called JAK2, and signal transducer and activator of transcription proteins, particularly STAT5.
IGF-1 Signalling
Growth hormone stimulates production of IGF-1 in the liver and in local tissues. IGF-1 contributes to many of the growth-related effects associated with the growth hormone system.
In children with open growth plates, the GH–IGF-1 axis participates in linear bone growth. In adults, the same hormonal system remains involved in body composition, bone turnover and the metabolism of protein, fat and carbohydrate.
Direct Metabolic Effects
Growth hormone also has direct metabolic actions that are not entirely dependent on circulating IGF-1. These include effects on fat mobilisation, protein metabolism and insulin sensitivity.
A mechanism is not a justification for non-medical use
Knowing that growth hormone affects metabolism does not establish that increasing exposure in a healthy person produces a favourable overall outcome. Hormonal systems are regulated within physiological ranges, and effects can become harmful when exposure is inappropriate.
What Is Established About Licensed Somatropin?
Unlike many substances discussed in research-peptide articles, somatropin has recognised clinical uses supported by regulatory evidence.
Somatropin has been evaluated through controlled trials, long-term registries, manufacturing comparability programmes and decades of specialist clinical practice.
Its authorisation is indication-specific. A medicine may be authorised for one diagnosed condition without being approved for unrelated goals such as anti-ageing, bodybuilding, general fatigue or improving athletic appearance.
Product-specific indications vary, but NICE guidance addresses its use for defined childhood growth disorders and severe adult growth hormone deficiency.
Treatment decisions require endocrine assessment because short stature, reduced energy, altered body composition and low IGF-1 can have many causes. A single random growth hormone measurement cannot normally diagnose deficiency because natural secretion is pulsatile.
Licensed evidence cannot be transferred to an unknown vial
Clinical trials of regulated somatropin do not establish the identity, potency or safety of a product obtained from an unverified research supplier.
Clinical Evidence in Children
NICE recommends somatropin for defined paediatric conditions rather than for every child who is shorter than average.
NICE technology appraisal guidance recommends somatropin as a treatment option for children with growth failure associated with:
- growth hormone deficiency
- Turner syndrome
- Prader–Willi syndrome
- chronic renal insufficiency
- being born small for gestational age with insufficient catch-up growth
- short stature homeobox-containing gene deficiency, known as SHOX deficiency
Eligibility and licensed indications vary by product and condition. Treatment is expected to be initiated and monitored by a paediatrician with specialist expertise in growth disorders.
Systematic Review Evidence
A systematic review supporting the NICE appraisal included 28 randomised controlled trials reported across 34 publications. Across the licensed childhood indications, somatropin increased growth-related outcomes compared with no treatment or control groups.
The size and certainty of the effect differed between conditions. Some trials measured short-term height velocity, while fewer provided final adult-height data.
A faster growth rate during one year is not identical to a confirmed difference in final adult height. Long-term interpretation must consider diagnosis, age at treatment, adherence, puberty, bone age and other clinical factors.
What the evidence does not establish
Paediatric somatropin trials do not justify unsupervised use to make a healthy child taller or to exceed a person’s genetically influenced growth pattern.
Clinical Evidence in Adults With Growth Hormone Deficiency
Adult replacement is intended for confirmed severe deficiency, not for normal age-related hormonal variation.
Adult growth hormone deficiency may begin during childhood or develop later because of pituitary or hypothalamic disease, surgery, radiotherapy, trauma or other recognised causes.
NICE recommends somatropin for adults only when defined diagnostic and clinical criteria are met. The guidance includes confirmation of severe growth hormone deficiency and assessment of impaired quality of life.
Randomised trials in adults with confirmed deficiency have reported changes in body composition, extracellular water, exercise-related measures and quality-of-life scores. The relevance of each outcome depends on the diagnosed population and the trial design.
This replacement evidence does not apply directly to adults with normal pituitary function. Restoring a deficient hormone towards a physiological range is not equivalent to producing supraphysiological exposure in a healthy person.
HGH 191AA Research in Healthy Adults, Sport and Ageing
Evidence in healthy people is less supportive than promotional claims often suggest.
Athletic Performance
Systematic reviews of placebo-controlled trials in healthy young adults have reported changes in lean body mass after growth hormone exposure. However, increases in measured lean mass may partly reflect extracellular fluid rather than newly functional muscle tissue.
Reviews have not demonstrated consistent improvements in muscle strength or aerobic exercise capacity that would justify broad performance claims.
Growth hormone remains prohibited in competitive sport regardless of whether a user believes it improves performance.
Anti-Ageing Claims
Growth hormone secretion changes with age, but age-related decline is not the same as pathological growth hormone deficiency.
A systematic review of randomised trials in healthy older adults found relatively small changes in body composition alongside increased adverse events, including swelling, joint symptoms and carpal tunnel syndrome.
The available evidence does not establish somatropin as an anti-ageing therapy or as a method for extending lifespan.
Body Composition
A reduction in measured fat mass or increase in lean mass does not necessarily translate into improved strength, mobility, health or long-term outcomes.
Claims should distinguish between a laboratory or imaging measurement and an outcome that meaningfully changes how a person feels or functions.
HGH 191AA Evidence at a Glance
The evidence is strong for defined replacement uses but does not validate research-market enhancement claims.
| Research or Use Area | Evidence Type | Current Evidence Status | Main Limitation |
|---|---|---|---|
| Confirmed childhood growth hormone deficiency | Randomised trials, long-term studies and clinical guidance | Established licensed use | Requires specialist diagnosis and product-specific monitoring |
| Selected childhood growth disorders | Condition-specific trials and NICE appraisal | Supported for defined indications | Results differ by diagnosis and do not apply to all short children |
| Severe adult growth hormone deficiency | Randomised trials and NICE criteria | Established replacement use in selected adults | Requires validated diagnostic assessment |
| Athletic performance in healthy adults | Small placebo-controlled trials and systematic reviews | No consistent performance benefit established | Body-composition changes may reflect fluid and do not reliably improve strength |
| Anti-ageing in healthy older adults | Randomised trials and systematic review | Not established | Small body-composition changes and increased adverse events |
| General fat-loss claims | Mechanistic and short-term experimental evidence | Not an approved general weight-management use | Metabolic effects occur alongside glucose and fluid-related risks |
| Research-market HGH 191AA vial equivalence | Product-specific analytical evidence required | Cannot be assumed | Residue count and HPLC purity do not establish biosimilarity |
| Long-term supraphysiological use | Limited controlled evidence | Safety not established | Misuse is difficult to study ethically and systematically |
Important Research and Interpretation Limitations
Somatropin has extensive clinical evidence, but that evidence must remain tied to the correct product and population.
- HGH 191AA is not a complete product specification.
- The 191-residue sequence does not prove correct protein folding.
- High chromatographic purity does not prove biological potency.
- Licensed somatropin evidence does not validate unlicensed research vials.
- Replacement therapy evidence applies to confirmed deficiency.
- Short-term height velocity is not the same as final adult height.
- Changes in lean mass may include additional extracellular water.
- Body-composition changes do not automatically improve physical performance.
- Age-related hormonal change is not equivalent to pituitary disease.
- Long-term risks of enhancement use are not well quantified.
- Adverse-event reporting is weaker outside regulated healthcare systems.
- Different recombinant expression systems produce different impurity risks.
- Biological medicines cannot be compared using sequence alone.
- International units do not prove identity or potency without a validated bioassay.
- Storage history can affect aggregation and activity.
- A research label does not establish lawful medicinal supply.
How HGH 191AA Should Be Analytically Characterised
Full-length recombinant growth hormone requires protein-level testing rather than a generic peptide purity report.
Intact Molecular Mass
Mass spectrometry should support the expected intact mass and help distinguish 191-residue somatropin from methionyl or modified variants.
Peptide Mapping
Enzymatic digestion followed by chromatography and mass spectrometry can confirm coverage across the protein sequence.
Disulphide-Bond Mapping
Analysis should confirm the expected cysteine pairings rather than merely the correct amino-acid composition.
Higher-Order Structure
Spectroscopic or comparative structural methods may be required to show that the protein adopts the expected conformation.
Monomer and Aggregate Testing
Size-exclusion chromatography can help measure dimers, oligomers and higher-molecular-weight aggregates.
Biological Activity
A validated receptor or cell-based assay is needed to establish functional potency rather than assuming activity from mass alone.
Host-Cell Contaminants
Testing should address residual host-cell proteins, host-cell DNA and process-related impurities.
Sterility and Endotoxin
Where relevant to the finished preparation, validated microbiological and bacterial-endotoxin testing must be separate from chemical purity.
What a Meaningful HGH 191AA Certificate Should Include
- Unambiguous identification as 191-residue somatropin
- Production-system information
- Observed intact molecular mass
- Peptide-map sequence coverage
- N-terminal identity
- Disulphide-bond confirmation
- Monomer and aggregate results
- Related proteins and degradation products
- Protein-content assay
- Validated biological-potency result
- Residual host-cell protein testing
- Residual host-cell DNA testing
- Endotoxin result where relevant
- Sterility result where relevant
- Batch-specific stability information
- Laboratory identity and method references
- A clear statement of tests not performed
Why “99% HPLC” Is Inadequate
Reverse-phase HPLC may show that one major chromatographic peak dominates the sample. It does not establish correct folding, receptor activity, disulphide bonding, aggregate content, host-cell contaminants or microbiological quality.
Sequence identity is not biosimilarity
A biosimilar somatropin medicine requires a structured comparison with an authorised reference product. A sequence claim and a single chromatogram do not meet that standard.
Somatropin Safety and Reported Adverse Effects
Known risks come from regulated medical use; unverified products add further manufacturing uncertainty.
Fluid Retention and Musculoskeletal Effects
Recognised adverse effects include fluid retention, peripheral swelling, joint discomfort, muscle pain, paraesthesia and carpal tunnel syndrome. These effects are reported more often in adults than in children.
Glucose Metabolism
Growth hormone can reduce insulin sensitivity. Official product information advises monitoring for altered glucose regulation, particularly in people with relevant risk factors.
Headache and Intracranial Hypertension
Headache can occur during treatment. Rare intracranial hypertension has been reported, particularly where severe headache is accompanied by visual symptoms, nausea or vomiting.
Thyroid and Adrenal Context
Growth hormone replacement can reveal or alter the management of other pituitary hormone deficiencies. Specialist monitoring may therefore include thyroid and adrenal assessment where clinically appropriate.
Growth-Related Paediatric Concerns
Children receiving treatment require monitoring for changes including progression of scoliosis, hip or knee symptoms associated with slipped capital femoral epiphysis and rare pancreatitis.
Malignancy
Active malignancy is a contraindication in authorised product information. Patients with a history of tumour treatment require specialist assessment and monitoring.
This does not mean that every exposure causes cancer. It means that growth-promoting hormonal signalling must be considered carefully where malignant disease is active or recurrence risk is relevant.
Risks Added by Unverified Products
- Incorrect or absent active protein
- 192-residue material sold as 191AA
- Incorrect protein quantity
- Reduced biological potency
- Protein aggregates
- Host-cell proteins
- Residual bacterial DNA
- Endotoxin contamination
- Microbial contamination
- Degradation caused by poor storage
- Certificates unrelated to the supplied batch
Licensed safety data do not protect an unknown product
The known benefit-to-risk profile of authorised somatropin applies to regulated products used for approved indications. It cannot be transferred to a research-market vial with uncertain manufacture.
Regulating HGH 191AA in the Peptides UK Market
Regulatory status checked on 21 July 2026.
Somatropin Is an Authorised Prescription Medicine
Licensed somatropin medicines exist in the UK for defined endocrine indications. They are prescription-only medicines and are expected to be prescribed and monitored through appropriate specialist care.
The existence of licensed somatropin does not authorise every product labelled HGH 191AA.
A research-market product cannot present itself as equivalent to a licensed medicine without the required authorisation and supporting evidence.
Controlled-Drug Status
Somatropin, somatotropin and somatrem are controlled as Class C substances under UK misuse-of-drugs legislation and are placed within Schedule 4 Part II of the Misuse of Drugs Regulations.
Manufacture, supply, possession with intent to supply, import and export can engage both medicines law and controlled-drug law. The precise legal position depends on the circumstances, authorisations and method of supply.
This article does not provide personal importation or possession advice. Independent legal advice should be obtained where required.
MHRA Product Classification
MHRA guidance explains that a product may be a medicine where it is presented as treating or preventing disease, or where it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.
Claims relating to growth, muscle, fat loss, recovery, anti-ageing, hormone replacement or physical performance may contribute to medicinal-product classification.
The phrase “Research Use Only” does not settle classification where the overall website, imagery, testimonials or instructions imply personal administration.
Advertising
Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product where the required marketing authorisation, registration or certificate is not in force.
This section provides general regulatory education rather than legal advice.
HGH 191AA and Competitive Sport
Growth hormone is prohibited at all times under the 2026 World Anti-Doping Code list.
The WADA 2026 Prohibited List includes growth hormone, its analogues and fragments within section S2.2.3.
The prohibition applies in and out of competition. It is not removed by a research label, a private purchase or the absence of obvious short-term effects.
An athlete with a genuine diagnosed medical condition may need to satisfy Therapeutic Use Exemption requirements. A prescription alone does not necessarily complete the anti-doping process.
Long-acting growth hormone analogues and products that release somatropin are also addressed by the prohibited-list framework.
Common HGH 191AA Claims Examined
Commercial claims often combine established replacement evidence with unsupported enhancement conclusions.
“191 amino acids proves pharmaceutical quality.”
Licensed somatropin does contain the 191-residue human growth hormone sequence.
Residue count does not prove folding, potency, aggregate control, sterility or authorised manufacture.
“HGH 191AA is simply a research peptide.”
Human growth hormone is a polypeptide chain.
Its size and structural complexity make it more accurately described as a recombinant protein hormone and biological medicine.
“Somatropin evidence proves any HGH vial works.”
Licensed products have substantial clinical evidence.
That evidence applies to regulated formulations and cannot verify an unrelated product.
“Growth hormone reliably improves athletic performance.”
Trials have reported changes in body composition.
Systematic reviews have not shown consistent improvements in strength or aerobic performance in healthy adults.
“Increased lean mass means more muscle.”
Lean-mass measurements include water and other non-fat tissues.
Growth hormone-related fluid retention can increase measured lean mass without producing an equivalent increase in functional muscle.
“Age-related GH decline is a deficiency.”
Growth hormone secretion changes with age.
Physiological ageing is not automatically the same as severe pituitary growth hormone deficiency.
“HGH is a proven anti-ageing treatment.”
Trials in healthy older adults have reported small body-composition changes.
Reviews also found increased adverse effects and did not establish improved longevity or broad functional benefit.
“A 99% HPLC certificate proves genuine somatropin.”
HPLC is one useful analytical method.
It cannot alone confirm the full sequence, correct folding, disulphide bridges, biological potency, aggregates or host-cell contaminants.
HGH 191AA Compared With Related Growth-Hormone Compounds
Similar names do not mean that the substances are interchangeable.
| Substance | Basic Identity | Relationship to Growth Hormone | Important Distinction |
|---|---|---|---|
| Endogenous 22 kDa HGH | Natural 191-residue pituitary protein | Predominant circulating human growth hormone | Secreted in physiological pulses |
| Somatropin | Recombinant 191-residue human growth hormone | Matches the predominant natural sequence | Licensed products are regulated biological medicines |
| Somatrem | 192-residue methionyl recombinant growth hormone | Contains an additional N-terminal methionine | Not chemically identical to 191AA somatropin |
| Long-acting GH products | Modified hormones or delivery technologies | Designed to extend exposure | Product-specific structure and regulatory evidence differ |
| HGH fragment 176–191 | Short C-terminal fragment | Contains only part of the HGH sequence | Not full-length growth hormone and not equivalent to somatropin |
| Growth hormone-releasing peptides | Separate peptides acting through release pathways | May influence endogenous hormone secretion in research | They are not HGH and do not contain the 191-residue chain |
How to Assess HGH 191AA and Peptides UK Evidence Critically
Use this checklist before accepting a scientific, quality or regulatory claim.
- Is the substance identified as somatropin?
- Is the complete 191-residue sequence supported?
- Has the N-terminus been checked for extra methionine?
- Were both disulphide bonds confirmed?
- Was higher-order structure assessed?
- Was biological potency measured?
- Were protein aggregates quantified?
- Were host-cell proteins tested?
- Was residual host-cell DNA measured?
- Does the certificate match the finished batch?
- Was storage stability demonstrated?
- Is HPLC being presented as the only quality test?
- Was the research performed in deficient patients or healthy people?
- Does a lean-mass change improve strength or function?
- Was the study randomised and placebo controlled?
- Was the outcome clinically meaningful?
- Is licensed medicine evidence being applied to an unknown vial?
- Is the product being promoted for an unlicensed purpose?
- Does the page address controlled-drug status?
- Does the page acknowledge WADA prohibition?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profileHGH 191AA UK Frequently Asked Questions
Evidence-led answers about somatropin, research-market products, testing and UK regulation.
What does HGH 191AA mean?
It refers to the predominant 22 kDa form of human growth hormone, which contains 191 amino-acid residues.
Is HGH 191AA the same as somatropin?
The term is usually intended to describe the same 191-residue protein sequence as somatropin. A product label alone does not prove pharmaceutical equivalence.
Is HGH 191AA a peptide?
It is a polypeptide chain, but its size and folded structure mean it is more accurately classified as a protein hormone.
How large is human growth hormone?
The predominant form contains 191 amino acids and has a molecular weight of approximately 22,125 daltons.
What is the difference between 191AA and 192AA HGH?
The 192-residue form contains an additional N-terminal methionine. Historical methionyl recombinant growth hormone is commonly associated with the name somatrem.
Does 191AA mean the product is genuine?
No. The claim does not prove correct sequence, folding, disulphide bonding, potency, purity or microbiological quality.
Is somatropin an approved medicine in the UK?
Yes. Licensed somatropin products are used for defined childhood growth disorders and severe adult growth hormone deficiency.
Is every HGH 191AA vial an approved medicine?
No. Approval applies to specific authorised products, manufacturers, formulations and indications.
Is somatropin prescription only?
Yes. Licensed somatropin is a prescription-only medicine in the UK.
Is somatropin a controlled drug in the UK?
Yes. Somatropin is controlled as a Class C substance and is listed in Schedule 4 Part II of the Misuse of Drugs Regulations.
Is HGH approved for bodybuilding?
No. Bodybuilding and physique enhancement are not approved UK indications for somatropin.
Does HGH improve athletic performance?
Systematic reviews have not shown consistent improvements in strength or aerobic performance in healthy adults despite some body-composition changes.
Is HGH an approved anti-ageing treatment?
No. Research in healthy older adults has not established broad anti-ageing or longevity benefits and has identified increased adverse effects.
Does increased lean mass always mean increased muscle?
No. Lean mass includes water, organs and other non-fat tissue. Growth hormone-related fluid retention can influence the measurement.
How is growth hormone deficiency diagnosed?
Diagnosis usually requires specialist endocrine assessment and validated testing. A single random blood growth hormone result is generally inadequate because secretion is pulsatile.
What side effects are associated with somatropin?
Reported effects include fluid retention, joint or muscle discomfort, paraesthesia, headache, carpal tunnel syndrome and altered glucose regulation. Product-specific risks and contraindications also apply.
Does HGH cause cancer?
It is inaccurate to say that every use causes cancer. However, active malignancy is a contraindication, and people with relevant tumour histories require specialist assessment and monitoring.
Why are protein aggregates important?
Aggregates may alter potency and can increase the possibility of an immune response. They require separate testing from reverse-phase HPLC purity.
Does 99% HPLC prove somatropin quality?
No. It does not establish folding, biological activity, disulphide bonds, aggregate content, host-cell impurities, endotoxin or sterility.
What should an HGH 191AA certificate include?
It should include intact mass, peptide mapping, N-terminal identity, disulphide mapping, aggregate testing, protein assay, biological potency and relevant process-impurity results.
Is HGH prohibited in sport?
Yes. Growth hormone, its analogues and fragments are prohibited at all times under the WADA 2026 list.
Does “Research Use Only” settle the UK legal position?
No. Regulators may consider the active substance, intended purpose, claims, presentation, testimonials and wider website content.
Does this article provide dosing or administration guidance?
No. It does not provide preparation, reconstitution, injection, dosing, cycling, bodybuilding or personal-use instructions.
Key Takeaways
- HGH 191AA usually refers to the predominant 191-residue form of human growth hormone.
- The recognised pharmaceutical active substance is somatropin.
- Human growth hormone is more accurately described as a protein hormone than a short peptide.
- The mature protein has a molecular weight of approximately 22,125 daltons.
- Correct folding and two disulphide bonds are essential parts of its structure.
- Somatropin is an established medicine for defined endocrine conditions.
- Licensed evidence does not validate an unrelated research-market vial.
- Somatropin is prescription only and controlled as a Class C substance in the UK.
- Growth hormone is prohibited under the WADA 2026 list.
- Evidence does not establish somatropin as a general anti-ageing or bodybuilding treatment.
- A 99% HPLC result cannot prove somatropin identity, potency or biological quality.
- Research-market products require protein-level analytical assessment rather than sequence claims alone.
Relevant It’s Me & You Clinic Research Resources
Explore related evidence-led content and practitioner profiles.
Research Peptides UK
Browse the wider educational series on peptide identity, biological evidence, certificates of analysis and UK regulation.
Browse the research peptide education libraryGrowth Hormone Fragment Research
Compare full-length somatropin with shorter growth-hormone fragments.
Browse related peptide guidesDr Rimas Geiga
Learn more about the clinic’s medical adviser with interests in metabolism, nutrition and healthy ageing.
View Dr Rimas Geiga’s profileDr Snieguole Geige
Explore the clinic’s approach to evidence-based patient education and informed healthcare decisions.
View Dr Snieguole Geige’s profileReferences
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins: somatropin annex. EMA scientific guideline
- European Medicines Agency. Somatropin BioPartners assessment report. Molecular characterisation includes the 191-residue sequence, 22 kDa mass and disulphide-bond arrangement. EMA assessment report
- European Medicines Agency. Omnitrope European Public Assessment Report. EMA medicine record
- European Medicines Agency. Somatropin referral and benefit-risk review. EMA referral record
- National Institute for Health and Care Excellence. Human growth hormone for the treatment of growth failure in children. Technology appraisal guidance TA188. NICE guidance
- National Institute for Health and Care Excellence. Recommendations for somatropin in childhood growth failure. NICE recommendations
- National Institute for Health and Care Excellence. Human growth hormone in adults with growth hormone deficiency. Technology appraisal guidance TA64. NICE guidance
- National Institute for Health and Care Excellence. British National Formulary entry for somatropin. BNF medicine record
- Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technology Assessment. 2010. PMID: 20849734. PubMed record
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2007;146(2):104–115. PMID: 17227934. PubMed record
- Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine. 2008;148(10):747–758. PMID: 18347346. PubMed record
- Hermansen K, Bengtsen M, Kjaer M, Vestergaard P, Jørgensen JOL. Impact of GH administration on athletic performance in healthy young adults: systematic review and meta-analysis. 2017. PMID: 28514721. PubMed record
- National Institute of Diabetes and Digestive and Kidney Diseases. National Hormone and Pituitary Program information concerning pituitary-derived growth hormone and Creutzfeldt–Jakob disease. NIDDK information
- Cambridge University Hospitals NHS Foundation Trust. Adult growth hormone replacement. NHS patient information
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Medicines and Healthcare products Regulatory Agency. A guide to what is a medicinal product. Guidance Note 8. MHRA classification guide
- Human Medicines Regulations 2012. Legislation.gov.uk
- Human Medicines Regulations 2012, Regulation 279. Advertising restriction
- Advisory Council on the Misuse of Drugs. Annual report January 2023 to December 2025. The report describes somatotropin, somatropin and somatrem as existing Class C controlled growth hormone medicines. ACMD report
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 list
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS guidance
